Denosumab (Prolia)

medicine injections

Denosumab (Prolia) is a biologic medication used to prevent fragile bones, also known as osteoporosis, and bone fractures. As a biologic drug, it is man-made and closely resembles naturally-occurring antibodies in the body. In this case, it stops a molecule, called RANKL, which normally causes bone turnover. By blocking RANKL, it helps to strengthen bones.

How to Take It

Denosumab is given as an injection just under the skin. It is given by your rheumatology provider or nursing staff. The usual dose is 60 mg every six months, and it should be taken with calcium (1000 - 1200 mg daily) and vitamin D (at least 400 IU) supplementation. Denosumab works quickly - within three days of an injection, the effects on reducing bone turnover can be detected in the blood; the drug also stays in the blood for several months after stopping the medicine. Denosumab may be given in combination with other agents to reduce bone turnover.

Side Effects

The most common side effects that patients experience are back pain, pain in the hands and feet, and increased cholesterol. The pain from denosumab can last a few days up to a few months after administration.

The rarer, but worrisome side effects include an increased risk for infections (especially if you’re already taking medications that lower your immune system), low calcium levels (called hypocalcemia), loss of blood supply tothe jawbone (called osteonecrosis of the jaw), and severe allergic reactions.

Tell Your Rheumatology Provider

Some symptoms may occur normally while taking denosumab, however, you should notify your rheumatology provider if you have these symptoms while taking this medication: tingling of the hands or around the mouth, new pain in the jaw, or fevers or other signs of infection.

Make sure to notify your other providers while you are taking this drug. If you are pregnant or considering pregnancy, let your provider know before starting this medication. Women should discuss birth control with their primary care providers or gynecologists. Breast-feeding should be avoided while taking denosumab because the drug can enter breast milk.

Updated December 2020 by Vaneet Sandhu, MD, and reviewed by the American College of Rheumatology Communications and Marketing Committee.

This information provided for general education only. Individuals should consult a qualified health care provider for professional medical advice, diagnosis and treatment of a medical or health condition.

© 2021 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us